Evidence map›Paper›PMID 21398307›Full record

ReviewCardiovascular research2011

Cardiac anaplerosis in health and disease: food for thought.

Christine Des Rosiers, François Labarthe, Steven G Lloyd, John C Chatham

Abstract readReview
In one paragraph

Review in Cardiovascular research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Proteomic analysis of mitochondrial biogenesis in cardiomyocytes differentiated from human induced pluripotent stem cells.American journal of physiology. Regulatory, integrative and comparative physiology · 2021
    Article
  15. Review
  16. Review
  17. Article
  18. Characterization and validation of a preventative therapy for hypertrophic cardiomyopathy in a murine model of the disease.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  19. Re-balancing cellular energy substrate metabolism to mend the failing heart.Biochimica et biophysica acta. Molecular basis of disease · 2020
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Christine Des RosiersDepartment of Nutrition, Montreal Heart Institute and Université de Montréal, Montreal, QC, Canada H3C 3J7. christine.des.rosiers@umontreal.ca
François Labarthe
Steven G Lloyd
John C Chatham

Funding

TYPE 2 DIABETES AND CARDIAC DYSFUNCTIONR01HL067464 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CHATHAM, JOHN C · 2000 to 2009
$1.9M
Mechanisms of glucosamine ischemic cardioprotectionR01HL079364 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CHATHAM, JOHN C · 2006 to 2010
$1.9M
Protein O-GlcNAcylation and the regulation of cardiac functionR01HL101192 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CHATHAM, JOHN C · 2010 to 2014
$1.5M
CIHR 9575NHLBI NIH HHS HL079364NHLBI NIH HHS HL101192NHLBI NIH HHS HL67464NHLBI NIH HHS R01 HL101192
6 · The paper itself

Abstract

There has been a resurgence of interest for the field of cardiac metabolism catalysed by the increased need for new therapeutic targets for patients with heart failure. The primary focus of research in this area to date has been on the impact of substrate selection for oxidative energy metabolism; however, anaplerotic metabolism also has significant interest for its potential cardioprotective role. Anaplerosis refers to metabolic pathways that replenish the citric acid cycle intermediates, which are essential to energy metabolism; however, our understanding of the role and regulation of this process in the heart, particularly under pathophysiological conditions, is very limited. Therefore, the goal of this article is to provide a foundation for future directions of research on cardiac anaplerosis and heart disease. We include an overview of anaplerotic metabolism, a critical evaluation of current methods available for its quantitation in the intact heart, and a discussion of its role and regulation both in health and disease as it is currently understood based mostly on animal studies. We also consider genetic diseases affecting anaplerotic pathways in humans and acute intervention studies with anaplerotic substrates in the clinics. Finally, as future perspectives, we will share our thoughts about potential benefits and practical considerations on modalities of interventions targeting anaplerosis in heart disease, including heart failure.

Indexed as

AnimalsCitric Acid CycleEnergy MetabolismHeart FailureHumansMyocardium

Identifiers

PMID21398307
PMCPMC3078802

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.